[1]Elfahham,HassanAttia;Elgemeie,GalanEldinHamza;Ibraheim,YusriaRizk;Elnagdi,MohamedHilmy[LiebigsAnnalenderChemie,1988,p.819-822]
[1]Elfahham,HassanAttia;Elgemeie,GalanEldinHamza;Ibraheim,YusriaRizk;Elnagdi,MohamedHilmy[LiebigsAnnalenderChemie,1988,p.819-822]
[1]Elfahham,HassanAttia;Elgemeie,GalanEldinHamza;Ibraheim,YusriaRizk;Elnagdi,MohamedHilmy[LiebigsAnnalenderChemie,1988,p.819-822]
[1]Elfahham,HassanAttia;Elgemeie,GalanEldinHamza;Ibraheim,YusriaRizk;Elnagdi,MohamedHilmy[LiebigsAnnalenderChemie,1988,p.819-822]
[1]Elgemeie;Fathy;Faddah;Ebeid;Elsaid[ArchivderPharmazie,1991,vol.324,#3,p.149-152]
Title: Jessica Kalra, et al. Validating the Use of a Luciferase Labeled Breast Cancer Cell Line, MDA435LCC6, as a Means to Monitor Tumor Progression and to Assess the Therapeutic Activity of an Established Anticancer Drug, Docetaxel (Dt) Alone or in Combination With the ILK Inhibitor, QLT0267. Cancer Biol Ther. 2011 May 1;11(9):826-38.
